126 related articles for article (PubMed ID: 37776843)
1. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Haque T; Cadenas FL; Xicoy B; Alfonso-Pierola A; Platzbecker U; Avivi I; Brunner AM; Chromik J; Morillo D; Patel MR; Falantes J; Leitch HA; Germing U; Preis M; Lenox L; Lauring J; Brown RJ; Kalota A; Mehta J; Pastore F; Gu J; Mistry P; Valcárcel D
Leuk Res; 2023 Nov; 134():107390. PubMed ID: 37776843
[TBL] [Abstract][Full Text] [Related]
2. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
Garcia-Manero G; Almeida A; Giagounidis A; Platzbecker U; Garcia R; Voso MT; Larsen SR; Valcarcel D; Silverman LR; Skikne B; Santini V
BMC Hematol; 2016; 16():12. PubMed ID: 27148452
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Vieito M; Moreno V; Spreafico A; Brana I; Wang JS; Preis M; Hernández T; Genta S; Hansen AR; Doger B; Galvao V; Lenox L; Brown RJ; Kalota A; Mehta J; Pastore F; Patel B; Mistry P; Gu J; Lauring J; Patel MR
Clin Cancer Res; 2023 Sep; 29(18):3592-3602. PubMed ID: 37491846
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
6. A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J; Rodriguez E; Maitland ML; Tsai FY; Socinski MA; Berlin JD; Thomas JS; Al Baghdadi T; Wang IM; Guo C; Golmakani M; Clark LN; Gazdoiu M; Li M; Tolcher AW
ESMO Open; 2024 Apr; 9(4):102961. PubMed ID: 38640748
[TBL] [Abstract][Full Text] [Related]
7. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Garcia-Manero G; Khoury HJ; Jabbour E; Lancet J; Winski SL; Cable L; Rush S; Maloney L; Hogeland G; Ptaszynski M; Calvo MC; Bohannan Z; List A; Kantarjian H; Komrokji R
Clin Cancer Res; 2015 Mar; 21(5):985-94. PubMed ID: 25480830
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Komrokji RS; Al Ali NH; Padron E; Cogle C; Tinsley S; Sallman D; Lancet JE; Lis AF
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):251-254. PubMed ID: 30852241
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
12. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Matsuda A; Tohyama K; Taniwaki M; Takeshita K; Takatoku M; Ozawa K
Int J Hematol; 2009 Oct; 90(3):353-360. PubMed ID: 19705057
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lenalidomide in myelodysplastic syndromes.
List A; Kurtin S; Roe DJ; Buresh A; Mahadevan D; Fuchs D; Rimsza L; Heaton R; Knight R; Zeldis JB
N Engl J Med; 2005 Feb; 352(6):549-57. PubMed ID: 15703420
[TBL] [Abstract][Full Text] [Related]
15. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
16. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
Steensma DP; Wermke M; Klimek VM; Greenberg PL; Font P; Komrokji RS; Yang J; Brunner AM; Carraway HE; Ades L; Al-Kali A; Alonso-Dominguez JM; Alfonso-Piérola A; Coombs CC; Deeg HJ; Flinn I; Foran JM; Garcia-Manero G; Maris MB; McMasters M; Micol JB; De Oteyza JP; Thol F; Wang ES; Watts JM; Taylor J; Stone R; Gourineni V; Marino AJ; Yao H; Destenaves B; Yuan X; Yu K; Dar S; Ohanjanian L; Kuida K; Xiao J; Scholz C; Gualberto A; Platzbecker U
Leukemia; 2021 Dec; 35(12):3542-3550. PubMed ID: 34172893
[TBL] [Abstract][Full Text] [Related]
17. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM; Baer MR; Yang J; Prebet T; Lee S; Schiller GJ; Dinner SN; Pigneux A; Montesinos P; Wang ES; Seiter KP; Wei AH; De Botton S; Arnan M; Donnellan W; Schwarer AP; Récher C; Jonas BA; Ferrell PB; Marzac C; Kelly P; Sweeney J; Forsyth S; Guichard SM; Brevard J; Henrick P; Mohamed H; Cortes JE
Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
[TBL] [Abstract][Full Text] [Related]
18. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
[TBL] [Abstract][Full Text] [Related]
19. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H
J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
Garcia-Manero G; Gore SD; Kambhampati S; Scott B; Tefferi A; Cogle CR; Edenfield WJ; Hetzer J; Kumar K; Laille E; Shi T; MacBeth KJ; Skikne B
Leukemia; 2016 Apr; 30(4):889-96. PubMed ID: 26442612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
